# Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment

> **NCT01336751** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 212 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Insulin glargine
- **DRUG:** 75% insulin lispro protamine suspension and 25 % insulin lispro injection

## Key facts

- **NCT ID:** NCT01336751
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-07
- **Primary completion:** 2002-12
- **Final completion:** 2002-12
- **Target enrollment:** 212 (ACTUAL)
- **Last updated:** 2011-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01336751

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01336751, "Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01336751. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*